PMC:6218602 / 7622-8333 JSONTXT

{"project":"2_test","denotations":[{"id":"30425662-3046553-41865333","span":{"begin":392,"end":394},"obj":"3046553"},{"id":"30425662-7977880-41865334","span":{"begin":396,"end":398},"obj":"7977880"},{"id":"30425662-9524789-41865335","span":{"begin":400,"end":402},"obj":"9524789"},{"id":"30425662-16518132-41865336","span":{"begin":594,"end":596},"obj":"16518132"}],"text":"Traditionally, for those patients who are unable to obtain adequate positive symptom control or sustain a response with at least 2 dopamine receptor-2 (D2)-blocking agents at therapeutic doses for at least 6 weeks, clozapine is the recommended drug of choice. An estimated 30–60% of these patients will respond to clozapine and have what can be described as a clozapine-responsive psychosis (10, 15, 16). Patients who do not have an optimal response to clozapine and continue to experience prominent positive symptoms have clozapine-resistant psychosis or an ultra-resistant psychotic disease (11). Currently, there are no therapies that address this most severe form of neural-dysconnectivity in schizophrenia."}